Business Context and Reporting Period
This Form 8-K Current Report is filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) for the reporting period ending December 30, 2024. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol EYEN. The filing primarily addresses the entry into a new material definitive agreement regarding an at-the-market (ATM) equity offering program and provides a brief financial update.
Key Financial Metrics
The filing provides limited financial data as of December 26, 2024:
- Cash and Cash Equivalents: $2.2 million.
- Debt Obligations: $10.1 million in principal and accrued interest owed under a Loan and Security Agreement with Avenue Capital Management II, L.P. and related funds.
- Historical ATM Sales: Under the previous agreement with Leerink Partners, the company sold an aggregate of $16,413,443 of common stock.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins for the current period.
Material Changes
The most significant change reported is the restructuring of the company's equity financing program:
- New Sales Agreement: On December 30, 2024, Eyenovia entered into an Amended and Restated Sales Agreement with Chardan Capital Markets, LLC as the new sales agent, replacing Leerink Partners LLC.
- Offering Capacity: The new agreement authorizes the sale of up to $50,000,000 of common stock via an at-the-market offering.
- Termination of Prior Program: On December 29, 2024, the company terminated the prior prospectus dated October 8, 2024, which allowed for the sale of up to $25,000,000 under the initial agreement with Leerink Partners.
- Commission Structure: The company will pay Chardan a commission of 3.0% of the gross sales proceeds.
Outlook, Risks, and Management Commentary
Management Commentary: The company is not obligated to make any sales under the new agreement. Sales will be conducted based on instructions from the company, including price, time, or size limits. The offering will terminate upon the sale of all shares or termination of the agreement.
Risks and Contingencies: The filing notes that the offering is subject to customary representations, warranties, and indemnification rights. It explicitly states that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful prior to registration.
Unusual Items: The filing highlights a significant liquidity position where debt obligations ($10.1 million) substantially exceed available cash ($2.2 million), necessitating the continuation of the ATM program to raise capital.
Investor Verification Checklist
- Verify the exact terms of the Amended and Restated Sales Agreement filed as Exhibit 1.1.
- Confirm the current status of the $10.1 million debt obligation with Avenue Capital and any upcoming maturity dates or covenant requirements.
- Monitor future prospectus supplements to track actual share sales and proceeds generated under the new $50 million ATM program.
- Review the company's most recent 10-K or 10-Q for detailed revenue, expense, and cash flow data not included in this 8-K.